Toledo Community Hospital Oncology Program (TCHOP) seeks funding to continue its ongoing Community Clinical Oncology Program to provide the most advanced knowledge and technology currently achieved through cancer prevention and treatment trials to both urban and rural communities throughout its catchment area. Since receiving original funding in 1982, the Toledo CCOP has grown to include 17 components and institutions within the consortium. The catchment area has expanded to include Northwest and Northeast Ohio, Southeast Michigan and Eastern Virginia. The Toledo CCOP's strengths are: 25 years of positively contributing to National Cancer Institute's success in community-based research;a strong record of accrual to both treatment and prevention/control trials;experienced and effective organizational management;dedicated physician participation;and leadership in scientific and committee activities with the cooperative groups. TCCOP has in place adequate plans and support personnel to follow-up participants enrolled in large prevention trials. Finally, TCCOP's improved data management and communication infrastructure will support increased accrual while maintaining appropriate standards in an effective efficient manner that assures quality and TCCOP's ability to meet requirements of the Research Base and Federal entities. With funding through the National Cancer Institute Community Clinical Oncology Program (U10), TCCOP will persist in contributing to the discovery of treatment options for people who have been devastated by a cancer diagnosis.
Clinical research trials are necessary to advance and improve treatment outcomes of patients diagnosed with cancer. The growing body of knowledge from previous clinical cancer research trials has promoted healthy lifestyles to prevent or postpone the onset of cancer. However, many questions remain unanswered which require community participation in cancer research.
|Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53|
|Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005|
|Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
|Atherton, Pamela J; Halyard, Michele Y; Sloan, Jeff A et al. (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer 21:1193-9|
|Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92|
|Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8|
|Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92|
|Pruthi, Sandhya; Qin, Rui; Terstreip, Shelby A et al. (2012) A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause 19:48-53|
|Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900|
Showing the most recent 10 out of 106 publications